Shots:
The first patient has been dosed in Australia in the P-I clinical trial evaluating the safety, tolerability & preliminary efficacy of IBI343 in patients with advanced solid tumors. The study also determines the MTD & RP2D
In both Claudin 18.2 high and low expression mice tumor-bearing models, the therapy showed a potent tumor growth inhibition efficacy and showed a tolerable safety profile in preclinical in vivo models along with a promising anti-tumor effect
IBI343 is a recombinant human anti-Claudin 18.2 monoclonal ADC that binds to the Claudin 18.2-expressing tumor cells. The therapy was developed by Innovent Biologics
Ref: PRNewswire | Image: Innovent
